<DOC>
	<DOCNO>NCT00380887</DOCNO>
	<brief_summary>The purpose study determine bioequivalence bioavailability four different Premarin/MPA test formulation versus current formulation Prempro .</brief_summary>
	<brief_title>Study Comparing Four New Formulations Premarin Healthy Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<criteria>1 . Healthy postmenopausal woman age 35 70 year 2 . Nonsmoker smoker le 10 cigarette per day 1 . History presence clot disorder 2 . History presence cancer 3 . Presence HIV , hepatitis B hepatitis C 4 . History drug alcohol abuse</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>bioavailability</keyword>
	<keyword>bioequivalence</keyword>
	<keyword>market product</keyword>
	<keyword>Premarin</keyword>
	<keyword>Medroxyprogesterone acetate</keyword>
	<keyword>MPA</keyword>
	<keyword>Postmenopausal</keyword>
	<keyword>vasomotor symptom</keyword>
</DOC>